# TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

> **NCT00576251** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 221 (actual)

## Conditions studied

- Ocular Inflammation Associated With Blepharaconjunctivitis

## Interventions

- **DRUG:** Tobramycin 0.3%/Dexamethasone 0.05%
- **DRUG:** TOBRADEX

## Key facts

- **NCT ID:** NCT00576251
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-02
- **Final completion:** 2008-03
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2010-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00576251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00576251, "TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00576251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*